Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Mahammedi · SciRah

Researcher profile · Semantic Scholar

H. Mahammedi

Share profile

H. Mahammedi — researcher profile on SciRah

h-index: 21
Works: 98
Citations: 3,743

Most-cited papers

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon, C. Drake, H. Scher, K. Fizazi +22 more
2014The Lancet Oncology1,412 citations Open access
Semantic Scholar
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Padmanee Sharma, R. Pachynski, V. Narayan, A. Flechon +11 more
2020Cancer Cell367 citations Open access
Semantic Scholar
A randomised controlled phase 3 trial of lutetium-177-PSMA-617 in taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)
M. Morris, D. Castellano, Ken Herrmann, J. de Bono +19 more
2024The Lancet228 citations Open access
Semantic Scholar
Atezolizumab plus cabozantinib versus cabozantinib for patients with renal cell carcinoma after progression with prior immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomized, open-label, phase 3 trial
S. Pal, L. Albiges, P. Tomczak, C. Suárez +19 more
2023The Lancet175 citations Open access
Semantic Scholar
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
K. Fizazi, C. Drake, T. M. Beer, E. Kwon +21 more
2020European Urology164 citations Open access
Semantic Scholar
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
C. Pfister, G. Gravis, A. Flechon, C. Chevreau +8 more
2022Journal of Clinical Oncology163 citations
Semantic Scholar
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
R. Flippot, C. Dalban, B. Laguerre, D. Borchiellini +22 more
2019Journal of Clinical Oncology129 citations
Semantic Scholar
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study
H. Mahammedi, E. Planchat, M. Pouget, X. Durando +11 more
2016Oncology125 citations
Semantic Scholar
Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case.
J. Dupond, H. Mahammedi, D. Prié, F. Collin +5 more
2005Bone117 citations
Semantic Scholar
Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
Padmanee Sharma, Russell Kent Pachynski, V. Narayan, A. Flechon +11 more
2019Journal of Clinical Oncology87 citations
Semantic Scholar
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
C. Pfister, G. Gravis, A. Flechon, C. Chevreau +8 more
2023The Lancet Oncology77 citations Open access
Semantic Scholar
LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
O. Sartor, D. C. Gauna, K. Herrmann, J. de Bono +16 more
2023Annals of Oncology72 citations
Semantic Scholar
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
K. Fizazi, M. Retz, D. Petrylak, Jeffrey C. Goh +23 more
2022Journal for ImmunoTherapy of Cancer60 citations Open access
Semantic Scholar
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
K. Fizazi, K. Chi, N. Shore, K. Herrmann +14 more
2025Annals of Oncology54 citations Open access
Semantic Scholar
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
Judith Passildas-Jahanmohan, J. Eymard, M. Pouget, F. Kwiatkowski +11 more
2021Cancer Medicine50 citations Open access
Semantic Scholar
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Y. Loriot, M. Texier, S. Culine, A. Flechon +16 more
2022European Urology40 citations Open access
Semantic Scholar
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
M. Pulido, G. Roubaud, A. Cazeau, H. Mahammedi +9 more
2015BMC Cancer29 citations Open access
Semantic Scholar
Detection of a mesenchymal tumor responsible for hypophosphatemic osteomalacia using FDG-PET.
J. Dupond, H. Mahammedi, N. Magy, O. Blagosklonov +2 more
2005European journal of internal medicine29 citations
Semantic Scholar
Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma
T. Herrmann, Cécile Mione, P. Montoriol, I. Molnar +3 more
2021Oncology24 citations
Semantic Scholar
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
J. Courcier, C. Dalban, B. Laguerre, S. Ladoire +17 more
2021European Urology24 citations Open access
Semantic Scholar
Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors
E. Thivat, I. Van-praagh, A. Bellière, M. Mouret-Reynier +6 more
2012Oncology22 citations
Semantic Scholar
Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study
T. Herrmann, A. Ginzac, I. Molnar, S. Bailly +2 more
2021Cancer Medicine20 citations Open access
Semantic Scholar
Denosumab Toxicity When Combined With Anti‐angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study
A. Guillot, C. Joly, P. Barthélémy, É. Meriaux +16 more
2019Clinical Genitourinary Cancer20 citations
Semantic Scholar
715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
D. Pouessel, M. Beylot-Barry, S. Esma, M. de Pontville +16 more
2021Annals of Oncology18 citations Open access
Semantic Scholar
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
E. Colomba, S. Jonas, J. Eymard, R. Delva +20 more
2023European Urology17 citations
Semantic Scholar
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer
L. Mbatchi, M. Gassiot, P. Pourquier, Alejando Goberna +6 more
2017Cancer Chemotherapy and Pharmacology16 citations
Semantic Scholar
Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.
B. Escudier, S. Chabaud, D. Borchiellini, G. Gravis +10 more
201715 citations
Semantic Scholar
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
J. de Bono, M. Morris, Oliver Sartor, Xiao X. Wei +12 more
2024Journal of Clinical Oncology13 citations
Semantic Scholar
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
S. Culine, V. Harter, C. Krucker, G. Gravis +9 more
2023Cancers12 citations Open access
Semantic Scholar
579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)
D. Petrylak, J. Pérez-Gracia, L. Lacombe, D. Bastos +16 more
2021Annals of Oncology12 citations Open access
Semantic Scholar
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
S. Culine, V. Harter, G. Gravis, A. Flechon +27 more
2021Clinical Genitourinary Cancer11 citations Open access
Semantic Scholar
The SEMITEP trial: De-escalating chemotherapy in low-volume metastatic seminoma based on early FDG-PET.
Y. Loriot, M. Texier, S. Culine, A. Flechon +15 more
202010 citations
Semantic Scholar
Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177 Lu-PSMA-617.
J. de Bono, M. Morris, A. O. Sartor, Xiao X. Wei +11 more
2025Journal of Clinical Oncology9 citations
Semantic Scholar
652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
C. Pfister, G. Gravis, A. Flechon, C. Chevreau +8 more
2021Annals of Oncology9 citations Open access
Semantic Scholar
Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study
Ke Zhou, A. Blanc-Lapierre, V. Seegers, M. Boisdron-Celle +9 more
2021Cancers9 citations Open access
Semantic Scholar
Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
S. Tagawa, O. Sartor, J. M. Piulats, F. Saad +16 more
2026NuclearMedicine8 citations
Semantic Scholar
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
N. Shore, Christian Gratzke, S. Feyerabend, P. Werbrouck +23 more
2024The Oncologist7 citations Open access
Semantic Scholar
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
R. Flippot, T. Telli, M. Velev, A. Fléchon +25 more
2024European Urology Oncology6 citations
Semantic Scholar
Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
C. Pfister, G. Gravis, A. Flechon, C. Chevreau +7 more
2023Journal of Clinical Oncology6 citations Open access
Semantic Scholar
A "missed" cryoglobulin: the importance of in vitro calcium concentration.
M. André, H. Mahammedi, O. Aumaître, A. Tridon +2 more
2000Annals of the Rheumatic Diseases6 citations
Semantic Scholar
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
S. Tagawa, O. Sartor, J. Piulats, Fred Saad +23 more
2026The Lancet5 citations
Semantic Scholar
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Emilien Billon, C. Dalban, S. Oudard, C. Chevreau +16 more
2023European Urology Oncology5 citations Open access
Semantic Scholar
COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)
V. Seegers, G. Rousseau, K. Zhou, A. Blanc-Lapierre +9 more
2023Cancers5 citations Open access
Semantic Scholar
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer
J. Ferrero, H. Mahammedi, G. Gravis, G. Roubaud +10 more
2023Pharmaceutics5 citations Open access
Semantic Scholar
Association of single nucleotide polymorphisms (SNPs) in CYP17A1 and SLCO2B1 genes and clinical outcome in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: results of the ABIGENE prospective study.
D. Borchiellini, H. Mahammedi, J. Viotti, G. Gravis +16 more
20185 citations
Semantic Scholar
[Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].
G. Dupic, D. Collangettes, A. Dillies, L. Calvet +3 more
2015Bulletin du Cancer5 citations
Semantic Scholar
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line
M. Pouget, C. Abrial, E. Planchat, I. Van-praagh +10 more
2015Oncology5 citations
Semantic Scholar
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
T. Choueiri, L. Albiges, P. Tomczak, C. Suárez +15 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19)
Ke Zhou, J. Raoul, A. Blanc-Lapierre, V. Seegers +10 more
2022Clinical Medicine Insights: Oncology4 citations Open access
Semantic Scholar
ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).
E. Colomba, S. Jonas, J. Eymard, R. Delva +16 more
20213 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Gravis×18
Invite
G. Gravis — researcher profile on SciRah
C. Chevreau×13
Invite
C. Chevreau — researcher profile on SciRah
A. Flechon×12
Invite
A. Flechon — researcher profile on SciRah
B. Laguerre×12
Invite
B. Laguerre — researcher profile on SciRah

×10

Invite

K. Fizazi — researcher profile on SciRah

Invite

F. Joly — researcher profile on SciRah

Invite

S. Culine — researcher profile on SciRah

Invite

G. Roubaud — researcher profile on SciRah

Invite

N. Houédé — researcher profile on SciRah

Invite

L. Albiges — researcher profile on SciRah

Invite

A. Guillot — researcher profile on SciRah

D. Borchiellini×7

Invite

D. Borchiellini — researcher profile on SciRah